Why the study?
Does sotatercept improve exercise capacity in patients with pulmonary arterial hypertension receiving stable background therapy?
Does sotatercept improve exercise capacity in patients with pulmonary arterial hypertension receiving stable background therapy?
Sotatercept improves exercise capacity in patients with pulmonary arterial hypertension already on stable background therapy.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Pooled analyses across trials further suggest that sotatercept may have a meaningful impact on mortality in patients with PAH.”
Supports adding sotatercept to background PAH therapy; challenges prior low-certainty evidence against benefit.
In patients with pulmonary arterial hypertension who were receiving stable background therapy, sotatercept resulted in a greater improvement in exercise capacity (as assessed by the 6-minute walk test) than placebo. (Funded by Acceleron Pharma, a subsidiary of MSD; STELLAR ClinicalTrials.gov number, NCT04576988.).
No takes yet. Share an insight, caveat, or question.
Hoeper et al. (2023) studied this question.